I-Hung Shih, PhD

I-Hung Shih, PhD., is a co-head of Wellington’s Biotech Private Investments Team where she leads a team of four dedicated investors in investment sourcing, diligence, and execution of investments in biotech companies seeking to improve the standard of care in medicine. She identifies innovative companies across the health care sector with lifesaving potential, such as high-impact drugs and therapies. In her role, I-Hung has overseen 38 investments across two funds, managing almost $800 million in committed capital while also collaborating closely with teams across Wellington’s approximately $60+ billion Global Health care business. She also works on team development, portfolio oversight and Limited Partner engagement. Outside of Wellington, I-Hung enjoys connecting with investors and scientists, most recently speaking at the Women’s Venture Capital Summit and the Third Rock Ventures Portfolio Summit. She is a lifelong learner and researcher, staying close to the science by attending yearly medical meetings hosted by the Society for Immunotherapy of Cancer, the American Society of Hematology, and the International Liver Congress.

Prior to joining Wellington Management in 2018, I-Hung worked as a senior biotech analyst at T Rowe Price covering US biotech stocks and a co-manager on the Institutional US Structured Research Fund (2016 – 2018). Previously, she was lead officer for US biopharma investment in public/private equity at Temasek International (2014 – 2016), and an associate in investment banking on the Credit Suisse Biotech Team where she advised biotech companies on financing strategy and managed more than $20 billion in strategic and financial transactions (2011 – 2014). She began her professional career at Gilead Sciences as a research scientist in biology and a senior manager for Commercial Strategies (2005 – 2011).